XNASMTVA
Market cap17mUSD
Jan 10, Last price
2.06USD
1D
-3.29%
1Q
-19.53%
Jan 2017
-100.00%
IPO
-100.00%
Name
Neurobo Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
104.52%
Rev. gr., 5y
%
Revenues
0k
Net income
-12m
L+103.92%
CFO
-11m
L-7.80%
Earnings
Mar 26, 2025
Profile
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 15,886 | 11,446 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (15,886) | (11,446) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (7,852) | ||||||||
Tax Rate | |||||||||
NOPAT | (15,886) | (3,594) | |||||||
Net income | (12,470) 103.92% | (6,115) -59.83% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (80) | 28,681 | |||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 134 | ||||||||
Long-term debt | 339 | ||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 708 | ||||||||
Net debt | (21,962) | (33,364) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (10,799) | (11,712) | |||||||
CAPEX | (50) | ||||||||
Cash from investing activities | (50) | 8 | |||||||
Cash from financing activities | (80) | 29 | |||||||
FCF | (16,132) | (3,381) | |||||||
| Balance | |||||||||
Cash | 22,435 | 33,364 | |||||||
Long term investments | |||||||||
Excess cash | 22,435 | 33,364 | |||||||
Stockholders' equity | (108,260) | (95,770) | |||||||
Invested Capital | 125,215 | 117,520 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 5,071 | 322 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (15,880) | (11,426) | |||||||
EV/EBITDA | |||||||||
Interest | 2,191 | ||||||||
Interest/NOPBT | |||||||||